Suppr超能文献

氨基葡萄糖、硫酸软骨素或安慰剂治疗髋或膝关节骨关节炎患者的效果:网络荟萃分析。

Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.

机构信息

Institute of Social and Preventive Medicine, University of Bern, Switzerland.

出版信息

BMJ. 2010 Sep 16;341:c4675. doi: 10.1136/bmj.c4675.

Abstract

OBJECTIVE

To determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee. Design Network meta-analysis. Direct comparisons within trials were combined with indirect evidence from other trials by using a Bayesian model that allowed the synthesis of multiple time points.

MAIN OUTCOME MEASURE

Pain intensity. Secondary outcome was change in minimal width of joint space. The minimal clinically important difference between preparations and placebo was prespecified at -0.9 cm on a 10 cm visual analogue scale.

DATA SOURCES

Electronic databases and conference proceedings from inception to June 2009, expert contact, relevant websites. Eligibility criteria for selecting studies Large scale randomised controlled trials in more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head. Results 10 trials in 3803 patients were included. On a 10 cm visual analogue scale the overall difference in pain intensity compared with placebo was -0.4 cm (95% credible interval -0.7 to -0.1 cm) for glucosamine, -0.3 cm (-0.7 to 0.0 cm) for chondroitin, and -0.5 cm (-0.9 to 0.0 cm) for the combination. For none of the estimates did the 95% credible intervals cross the boundary of the minimal clinically important difference. Industry independent trials showed smaller effects than commercially funded trials (P=0.02 for interaction). The differences in changes in minimal width of joint space were all minute, with 95% credible intervals overlapping zero. Conclusions Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.

摘要

目的

确定氨基葡萄糖、软骨素或两者联合应用对髋关节或膝关节骨关节炎的关节疼痛和疾病放射学进展的影响。

设计

网络荟萃分析。通过贝叶斯模型,将试验内的直接比较与来自其他试验的间接证据相结合,该模型允许对多个时间点进行综合。

主要观察指标

疼痛强度。次要观察指标为关节间隙最小宽度的变化。药物与安慰剂之间的最小临床重要差异在 10cm 视觉模拟量表上预先设定为-0.9cm。

资料来源

电子数据库和会议记录,从开始到 2009 年 6 月,专家联系,相关网站。

纳入研究的标准

在 200 多名膝关节或髋关节骨关节炎患者中进行的大规模随机对照试验,比较氨基葡萄糖、软骨素或两者联合与安慰剂或头对头的药物。

结果

纳入 10 项试验共 3803 例患者。与安慰剂相比,氨基葡萄糖的疼痛强度总体差异为-0.4cm(95%可信区间-0.7 至-0.1cm),软骨素为-0.3cm(-0.7 至 0.0cm),联合用药为-0.5cm(-0.9 至 0.0cm)。在这些估计中,95%可信区间都没有跨越最小临床重要差异的边界。独立于行业的试验显示的效果比商业化资助的试验小(交互检验 P=0.02)。关节间隙最小宽度变化的差异都很小,95%可信区间与零重叠。

结论

与安慰剂相比,氨基葡萄糖、软骨素及其联合用药并不能减轻关节疼痛,也不能影响关节间隙变窄。卫生当局和健康保险公司不应承担这些药物的费用,也不应鼓励未接受治疗的新患者处方这些药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7353/4787883/87a9e28885a6/wans734756.f1_default.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验